South Korea’s newest billionaire is Lee Sang-hoon, founder of ABL Bio, after it struck a $2.6 billion licensing and joint ...

Eli Lilly has signed an agreement with ABL Biotech for access to the South Korean biotech's Grabody platform to develop ...

Eli Lilly's $2.6 billion agreement with ABL Bio focuses on developing therapeutics using the Grabody Platform for bispecific ...

South Korean clinical-stage biotech ABL Bio has entered license, research and collaboration agreement with US pharma major ...

Eli Lilly posts 54% revenue growth, raises guidance, and drives innovation in obesity and diabetes care. Read here for an ...

Eli Lilly has penned a research pact worth $1.2 billion in biobucks with SanegeneBio to help pinpoint cardiometabolic RNAi ...

Eli Lilly invests 22 billion won in ABL Bio to fund Grabody research Lilly to receive 175,079 ABL Bio shares as part of strategic R&D partnership ...

Eli Lilly has broken free from the Big Pharma pack. Fueled by sky-high expectations for the GLP-1 market, Lilly has achieved ...

ABL Bio Inc. inked a license and research agreement with Eli Lilly and Co. worth up to $2.6 billion to develop multiple therapeutics using the Grabody-B platform. Under the terms announced Nov. 12, ...

If Eli Lilly's obesity pill orforglipron is approved and priced around $200 per month, analysts at Truist predict patients ...

Among the medicines to be produced at the site will be orforglipron, the company’s oral small-molecule GLP-1 receptor agonist.